Analysts have been eager to weigh in on the Healthcare sector with new ratings on Chimerix (NASDAQ:CMRX) and Madrigal Pharmaceuticals Inc (NASDAQ:MDGL).
Chimerix (CMRX)
In a report released today, Phil Nadeau from Cowen & Co. maintained a Hold rating on Chimerix, with a price target of $6. The company’s shares opened today at $4.51.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 13.2% and a 55.7% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Voyager Therapeutics Inc.
Currently, the analyst consensus on Chimerix is a Moderate Buy with an average price target of $8.
See today’s analyst top recommended stocks >>
Madrigal Pharmaceuticals Inc (MDGL)
Cowen & Co. analyst Ritu Baral maintained a Buy rating on Madrigal Pharmaceuticals Inc today. The company’s shares opened today at $244.72.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 34.5% and a 56.1% success rate. Baral covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Global Blood Therapeutics, and Intra-Cellular Therapies.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Madrigal Pharmaceuticals Inc with a $321.17 average price target, which is a 31.2% upside from current levels. In a report released today, Oppenheimer also maintained a Buy rating on the stock with a $300 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.